196 related articles for article (PubMed ID: 32915357)
1. APOL1 polymorphism modulates sphingolipid profile of human podocytes.
Valsecchi M; Cazzetta V; Oriolo F; Lan X; Piazza R; Saleem MA; Singhal PC; Mavilio D; Mikulak J; Aureli M
Glycoconj J; 2020 Dec; 37(6):729-744. PubMed ID: 32915357
[TBL] [Abstract][Full Text] [Related]
2. APOL1 risk variants cause podocytes injury through enhancing endoplasmic reticulum stress.
Wen H; Kumar V; Lan X; Shoshtari SSM; Eng JM; Zhou X; Wang F; Wang H; Skorecki K; Xing G; Wu G; Luo H; Malhotra A; Singhal PC
Biosci Rep; 2018 Aug; 38(4):. PubMed ID: 29967295
[TBL] [Abstract][Full Text] [Related]
3. Disrupted apolipoprotein L1-miR193a axis dedifferentiates podocytes through autophagy blockade in an APOL1 risk milieu.
Kumar V; Ayasolla K; Jha A; Mishra A; Vashistha H; Lan X; Qayyum M; Chinnapaka S; Purohit R; Mikulak J; Saleem MA; Malhotra A; Skorecki K; Singhal PC
Am J Physiol Cell Physiol; 2019 Aug; 317(2):C209-C225. PubMed ID: 31116585
[TBL] [Abstract][Full Text] [Related]
4. APOL1-G0 protects podocytes in a mouse model of HIV-associated nephropathy.
Bruggeman LA; Wu Z; Luo L; Madhavan S; Drawz PE; Thomas DB; Barisoni L; O'Toole JF; Sedor JR
PLoS One; 2019; 14(10):e0224408. PubMed ID: 31661509
[TBL] [Abstract][Full Text] [Related]
5. RNA sequencing of isolated cell populations expressing human APOL1 G2 risk variant reveals molecular correlates of sickle cell nephropathy in zebrafish podocytes.
Bundy JL; Anderson BR; Francescatto L; Garrett ME; Soldano KL; Telen MJ; Davis EE; Ashley-Koch AE
PLoS One; 2019; 14(6):e0217042. PubMed ID: 31158233
[TBL] [Abstract][Full Text] [Related]
6. Effect of
Haque S; Patil G; Mishra A; Lan X; Popik W; Malhotra A; Skorecki K; Singhal PC
Biosci Rep; 2017 Apr; 37(2):. PubMed ID: 28385815
[TBL] [Abstract][Full Text] [Related]
7. Impact of APOL1 polymorphism and IL-1β priming in the entry and persistence of HIV-1 in human podocytes.
Mikulak J; Oriolo F; Portale F; Tentorio P; Lan X; Saleem MA; Skorecki K; Singhal PC; Mavilio D
Retrovirology; 2016 Sep; 13(1):63. PubMed ID: 27599995
[TBL] [Abstract][Full Text] [Related]
8. Novel Human Podocyte Cell Model Carrying G2/G2 APOL1 High-Risk Genotype.
Ekulu PM; Adebayo OC; Decuypere JP; Bellucci L; Elmonem MA; Nkoy AB; Mekahli D; Bussolati B; van den Heuvel LP; Arcolino FO; Levtchenko EN
Cells; 2021 Jul; 10(8):. PubMed ID: 34440683
[TBL] [Abstract][Full Text] [Related]
9. APOL1 risk variants enhance podocyte necrosis through compromising lysosomal membrane permeability.
Lan X; Jhaveri A; Cheng K; Wen H; Saleem MA; Mathieson PW; Mikulak J; Aviram S; Malhotra A; Skorecki K; Singhal PC
Am J Physiol Renal Physiol; 2014 Aug; 307(3):F326-36. PubMed ID: 24899058
[TBL] [Abstract][Full Text] [Related]
10. DGAT2 Inhibition Potentiates Lipid Droplet Formation To Reduce Cytotoxicity in APOL1 Kidney Risk Variants.
Chun J; Riella CV; Chung H; Shah SS; Wang M; Magraner JM; Ribas GT; Ribas HT; Zhang JY; Alper SL; Friedman DJ; Pollak MR
J Am Soc Nephrol; 2022 May; 33(5):889-907. PubMed ID: 35232775
[TBL] [Abstract][Full Text] [Related]
11. Recruitment of APOL1 kidney disease risk variants to lipid droplets attenuates cell toxicity.
Chun J; Zhang JY; Wilkins MS; Subramanian B; Riella C; Magraner JM; Alper SL; Friedman DJ; Pollak MR
Proc Natl Acad Sci U S A; 2019 Feb; 116(9):3712-3721. PubMed ID: 30733285
[TBL] [Abstract][Full Text] [Related]
12. APOL1 risk variants affect podocyte lipid homeostasis and energy production in focal segmental glomerulosclerosis.
Ge M; Molina J; Ducasa GM; Mallela SK; Varona Santos J; Mitrofanova A; Kim JJ; Liu X; Sloan A; Mendez AJ; Banerjee S; Liu S; Szeto HH; Shin MK; Hoek M; Kopp JB; Fontanesi F; Merscher S; Fornoni A
Hum Mol Genet; 2021 Apr; 30(3-4):182-197. PubMed ID: 33517446
[TBL] [Abstract][Full Text] [Related]
13. Apolipoprotein L1 (APOL1) renal risk variant-mediated podocyte cytotoxicity depends on African haplotype and surface expression.
Gupta N; Waas B; Austin D; De Mazière AM; Kujala P; Stockwell AD; Li T; Yaspan BL; Klumperman J; Scales SJ
Sci Rep; 2024 Feb; 14(1):3765. PubMed ID: 38355600
[TBL] [Abstract][Full Text] [Related]
14. APOL1 renal risk variants promote cholesterol accumulation in tissues and cultured macrophages from APOL1 transgenic mice.
Ryu JH; Ge M; Merscher S; Rosenberg AZ; Desante M; Roshanravan H; Okamoto K; Shin MK; Hoek M; Fornoni A; Kopp JB
PLoS One; 2019; 14(4):e0211559. PubMed ID: 30998685
[TBL] [Abstract][Full Text] [Related]
15. Exon 4-encoded sequence is a major determinant of cytotoxicity of apolipoprotein L1.
Khatua AK; Cheatham AM; Kruzel ED; Singhal PC; Skorecki K; Popik W
Am J Physiol Cell Physiol; 2015 Jul; 309(1):C22-37. PubMed ID: 25924622
[TBL] [Abstract][Full Text] [Related]
16. Apolipoprotein L1-Specific Antibodies Detect Endogenous APOL1 inside the Endoplasmic Reticulum and on the Plasma Membrane of Podocytes.
Scales SJ; Gupta N; De Mazière AM; Posthuma G; Chiu CP; Pierce AA; Hötzel K; Tao J; Foreman O; Koukos G; Oltrabella F; Klumperman J; Lin W; Peterson AS
J Am Soc Nephrol; 2020 Sep; 31(9):2044-2064. PubMed ID: 32764142
[TBL] [Abstract][Full Text] [Related]
17. Alterations in plasma membrane ion channel structures stimulate NLRP3 inflammasome activation in APOL1 risk milieu.
Jha A; Kumar V; Haque S; Ayasolla K; Saha S; Lan X; Malhotra A; Saleem MA; Skorecki K; Singhal PC
FEBS J; 2020 May; 287(10):2000-2022. PubMed ID: 31714001
[TBL] [Abstract][Full Text] [Related]
18. Apolipoprotein L1 (APOL1) cation current in HEK-293 cells and in human podocytes.
Vandorpe DH; Heneghan JF; Waitzman JS; McCarthy GM; Blasio A; Magraner JM; Donovan OG; Schaller LB; Shah SS; Subramanian B; Riella CV; Friedman DJ; Pollak MR; Alper SL
Pflugers Arch; 2023 Mar; 475(3):323-341. PubMed ID: 36449077
[TBL] [Abstract][Full Text] [Related]
19. Disruption of APOL1-miR193a Axis Induces Disorganization of Podocyte Actin Cytoskeleton.
Kumar V; Paliwal N; Ayasolla K; Vashistha H; Jha A; Chandel N; Chowdhary S; Saleem MA; Malhotra A; Chander PN; Skorecki K; Singhal PC
Sci Rep; 2019 Mar; 9(1):3582. PubMed ID: 30837512
[TBL] [Abstract][Full Text] [Related]
20. Domain-Specific Antibodies Reveal Differences in the Membrane Topologies of Apolipoprotein L1 in Serum and Podocytes.
Gupta N; Wang X; Wen X; Moran P; Paluch M; Hass PE; Heidersbach A; Haley B; Kirchhofer D; Brezski RJ; Peterson AS; Scales SJ
J Am Soc Nephrol; 2020 Sep; 31(9):2065-2082. PubMed ID: 32764138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]